SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin who are ineligible for or decline radical cystectomy.

被引：3
|
作者：
Van der Heijden, Michiel Simon
Cutie, Christopher
Hampras, Shalaka
Indoria, Charu
Stewart, Rachel
Acharya, Milin
Stromberg, Katherine
Li, Xiang
Beeharry, Neil
Maffeo, John
Jacob, Joseph M.
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Janssen Res & Dev, Clin Oncol, Lexington, MA USA
[3] Janssen Res & Dev, Clin Biostat, Raritan, NJ USA
[4] Janssen Res & Dev, Clin Oncol, Spring House, PA USA
[5] Upstate Med Univ, Dept Urol, Syracuse, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS593
引用
收藏
页数：3
相关论文
共 17 条
  • [11] TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
    Necchi, A.
    Guerrero-Ramos, F.
    Crispen, P. L.
    Imbroda, B. Herrera
    Garje, R.
    Powles, T. B.
    Peyton, C. C.
    Pradere, B.
    Ku, J. H.
    Shore, N. D.
    Boegemann, M.
    Preston, M. A.
    Xylinas, E.
    Gong, C.
    Najmi, S.
    Hasan, M.
    Stitou, H.
    Bhanvadia, S.
    Sweiti, H.
    Psutka, S. P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1271 - 1272
  • [12] First-line Maintenance Therapy in Adult Patients with BCG-naive High-risk - non-muscle-invasive Bladder Cancer Open-label, multicenter, randomized Phase 3 Study to evaluate the Efficacy and Safety of TAR-200 in combination with Cetrelimab versus TAR-200 Monotherapy versus intravesical Bacillus Calmette-Guerin (BCG) in Patients with BCG-naive High-risk non-muscle-invasive Bladder Cancer (HR-NMIBC) - SUNRISE-3-AB 85/23 of AUO
    Rexer, H.
    Stenzl, A.
    Ohlmann, C. -H.
    UROLOGIE, 2024, 63 (01): : 135 - 136
  • [13] Results from SunRISe-1 in patients (Pts) with bacillus CalmetteeGuerin (BCG)-unresponsive high-risk non emuscle-invasive bladder cancer (HR NMIBC) receiving TAR200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1343 - S1344
  • [14] Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
    Jacob, Joseph M.
    Guerrero-Ramos, Felix
    Xylinas, Evanguelos
    Simone, Giuseppe
    Lotan, Yair
    Pieczonka, Christopher Michael
    Arentsen, Harm
    Necchi, Andrea
    Kulkarni, Girish S.
    Patel, Manish
    Cahn, David J.
    Nam, Jong Kil
    Boegemann, Martin
    Hampras, Shalaka
    Stromberg, Katherine
    Martin, Jason L.
    Shulka, Abhijit
    Sweiti, Hussein
    Van Der Heijden, Michiel Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 701 - 701
  • [15] Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guerin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
    Kamat, Ashish M.
    Shariat, Shahrokh
    Steinberg, Gary D.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Nam, Kijoeng
    Kapadia, Ekta
    Shore, Neal D.
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [16] A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.
    Hahn, Noah M.
    Chang, Sam
    Meng, Maxwell
    Shore, Neal D.
    Konety, Badrinath R.
    Steinberg, Gary D.
    Gschwend, Juergen
    Nishiyama, Hiroyuki
    Palou, Joan
    Taylor, John A.
    Lambert, Alexandre
    Zhu, Li
    Maeda, Toshiki
    Raybold, Bradley
    Fischer, Bruce S.
    Jeyamohan, Chandrika
    Zardavas, Dimitrios
    Witjes, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
    Singer, Eric
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    de Wit, Ronald
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Baranwal, Pranshu
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    Shore, Neal D.
    JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
12